Tier 2 — strong

Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms

M Pfeuffer, A Auinger, U Bley, I Kraus-Stojanowic, C Laue, P Winkler, C E Rüfer, J Frank, C Bösch-Saadatmandi, G Rimbach, J Schrezenmeir
Nutrition, metabolism, and cardiovascular diseases : NMCD 2013 23(5):403

Bibliography

PubMed
PMID 22118955
DOI
10.1016/j.numecd.2011.08.010
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignDouble-blind placebo-controlled crossover trial with APOE subgroup analysis
ModelHuman intervention research
Sample49 healthy men
InterventionQuercetin 150 mg/day or placebo
Duration8 weeks per period; 3-week washout
EndpointsBlood pressure; Lipid measurements

What the study showed, in plain terms

Published in 2013, this source examined cardiovascular and metabolic health. Design: Double-blind placebo-controlled crossover trial with APOE subgroup analysis. Sample/model: 49 healthy men. The exposure or intervention was Quercetin 150 mg/day or placebo. Follow-up or treatment period: 8 weeks per period; 3-week washout.

Endothelial function did not improve. Selected anthropometric, postprandial pressure, and lipid measures changed, while tumor necrosis factor alpha increased.

Mixed surrogate outcomes and small genotype subgroups limit inference. The results do not establish a consistent anti-inflammatory effect or prevention of metabolic disease.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Endothelial function did not improve.
  • Selected anthropometric, postprandial pressure, and lipid measures changed, while tumor necrosis factor alpha increased.
  • The recorded outcome domains were Blood pressure; Lipid measurements.
  • The result applies to the tested exposure: Quercetin 150 mg/day or placebo; 8 weeks per period; 3-week washout.

What this study can and cannot tell us

  • Mixed surrogate outcomes and small genotype subgroups limit inference. The results do not establish a consistent anti-inflammatory effect or prevention of metabolic disease.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 2
Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension
Valentyna Volodymyrivna Chopyak et al. · Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti · 2025
Tier 2
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN
Maryana I Prokosa et al. · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2022
Tier 2
Supplementation of the Pure Flavonoids Epicatechin and Quercetin Affects Some Biomarkers of Endothelial Dysfunction and Inflammation in (Pre)Hypertensive Adults: A Randomized Double-Blind, Placebo-Controlled, Crossover Trial
James I Dower et al. · The Journal of nutrition · 2015

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology